PECS-2 for Breast Surgery

Anesthesia Clinical Trial

Official title:

Regional Anesthesia for Breast Cancer Surgery, Effects on Postoperative Wellbeing and Disease Recurrence.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03117894
• Other study ID #: UmeaU-PECS
• Status: Completed
• Phase: N/A
• Start date: May 23, 2017
• Est. completion date: October 22, 2020

Study information

• Verified date: May 2021
• Source: Umeå University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is no consensus regarding which alternative is the best anesthesia for breast surgery, general anesthesia and morphine for postoperative analgesia or a combination of regional anesthesia and general anesthesia that possibly attenuates or abolishes the need for morphine.

The current study aims to determine which of the two strategies that is best in relation to postoperative pain, nausea and risk of recurrence of the disease.

Description:

Surgery for suspected or confirmed breast cancer is a common procedure world wide. The Swedish National board of health- and welfare reports that > 7000 women is diagnosed with breast cancer each year in Sweden.

Surgery always comes at the cost of a painful stimuli. It is of great importance that the anesthetist has anticipated this pain and has a plan to handle it.

The most common way to do this is to anesthetise the patient (put him or her to sleep, also called a General Anesthesia (GA)) for the surgical procedure and administer a strong analgesic (usually morphine) before the patient is awaken. Morphine has side-effects.

Another possible plan is to rely on a Regional Anesthesia (RA) (block pain from a certain part of the body) to take care of the pain, both during and after the surgery. Thereby this patient may be awake during the surgery. The two strategies may also be combined. That is, a regional anesthesia is applied before surgery but the patient is also put to sleep. The regional anesthesia is then fully effective when the patient is awaken and no strong analgesics are administered. The approach with a regional anesthesia is common in orthopedic surgery, either in combination with or without a general anesthesia.

For surgery on the breast, there has been few alternatives available for regional anesthesia. They have been considered to invasive for regular use and not been incorporated in clinical praxis as a routine.

The praxis of regional anesthesia has expanded tremendously in recent years. This is attributed to the increased use of ultrasound as a guide for the injection of anesthetic compounds in proximity to the nerves. The pectoral nerve block (PECS) was first described in 2011. It has since then been developed further and is much more feasible than the older alternatives for regional anesthesia covering the breast.

Therefore it has gained some popularity and a few studies on its performance have been published in recent years. It is still not clear though, if it really confers the patient a better postoperative situation regarding pain and nausea.

Further, observational studies have suggested that malignant disease is spread and hence recurs less often if the surgery is performed in conjunction with a regional anesthesia. These results have not yet been confirmed in randomized trials. Therefore, the investigators will use the data from the current study and also look if there is a difference between the study groups regarding recurrence of the disease and mortality three and five years after inclusion in the study.

A subgroup analysis will be made on the patients that has a mastectomy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: October 22, 2020
• Est. primary completion date: October 22, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: Unilateral surgery on the breast because of suspected malign disease.

Exclusion Criteria:

Bilateral surgery

Metastases other than in the axilla

Body Mass Index (BMI) > 35

Not able to communicate in Swedish

Dementia

American Society of Anesthesiology (ASA) 4 or 5

Chronic pain treatment (use of opiates or medicine for neuropathic pain > 7 days the last month)

Known allergy to Morphine or Ropivacaine

Congestive Heart Failure, New York Heart Association (NYHA) IIIB or worse

Chronic renal failure (S-creatinine increased)

Immunosuppression (more than 10 mg daily of Prednisolone or stronger medication)

No axillary exploration planned

Related Conditions & MeSH terms

• Anesthesia
• Anesthesia Morbidity
• Breast Neoplasm Female
• Breast Neoplasms
• Regional Anesthesia
• Regional Anesthesia Morbidity

Intervention

Drug:
• Ropivacaine 5 mg/ml, 35 ml
Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
• Remifentanil 50 microg/ml
The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
• Betamethason 4 mg
Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
• Paracetamol 1,5 g
Administered preoperatively to prevent pain postoperatively.
• Propofol
The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
• Arcoxia, 120 mg
Administered preoperatively to prevent pain postoperatively.
• Ondansetron 4 mg
Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
• Morphine
Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.

Locations

Country	Name	City	State
Sweden	Östersund Hospital	Östersund	Jämtland

Sponsors (1)

Lead Sponsor	Collaborator
Umeå University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Opiate consumption	The cumulative consumption of opiates (Morphine). This is the most often used way to asses the efficacy of the regional anesthesia that the intervention consists of.	48 hours
Primary	All cause mortality	This is to investigate the possible effect that a regional anesthesia may have on recurrence of a malignant tumor.	3 years and 5 years.
Secondary	Postoperative Nausea and Vomiting (PONV)	PONV is common after general anesthesia and more so if opiates are used for analgesia. Measured on an ordinal scale 0=no PONV, 1=nausea, 2=vomiting, 3=repeated vomiting	48 hours
Secondary	Actual pain score	To see if patients with a regional anesthesia have more or less pain than patients with intravenous Morphine as postoperative analgesia.	48 hours
Secondary	Recurrence of breast neoplasm	Recurrence of breast neoplasm	3 and 5 years
Secondary	Chronic Pain	Pain after 6 months as assessed in a telephone interview, measured as Numeric Rate Scale (0-10).	6 (5-7) months after surgery